In the last trading session, 1.67 million shares of the Cytokinetics Inc (NASDAQ:CYTK) were traded, and its beta was 0.83. Most recently the company’s share price was $39.81, and it changed around $1.16 or 3.00% from the last close, which brings the market valuation of the company to $4.74B. CYTK currently trades at a discount to its 52-week high of $73.76, offering almost -85.28% off that amount. The share price’s 52-week low was $32.74, which indicates that the current value has risen by an impressive 17.76% since then. We note from Cytokinetics Inc’s average daily trading volume that its 10-day average is 2.96 million shares, with the 3-month average coming to 1.89 million.
Cytokinetics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.32. If we narrow it down even further, the data shows that 0 out of 21 analysts rate the stock as a Sell; another 8 rate it as Overweight. Among the rest, 3 recommended CYTK as a Hold, whereas 10 deemed it a Buy, and 0 rated it as Underweight. Cytokinetics Inc is expected to report earnings per share of -1.36 for the current quarter.
Cytokinetics Inc (NASDAQ:CYTK) trade information
Instantly CYTK has showed a green trend with a performance of 3.00% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 40.02 on recent trading dayincreased the stock’s daily price by 0.52%. The company’s shares are currently down -15.37% year-to-date, but still up 10.61% over the last five days. On the other hand, Cytokinetics Inc (NASDAQ:CYTK) is -10.26% down in the 30-day period. We can see from the shorts that 14.33 million shares have been sold at a short interest cover period of 8.42 day(s).
The consensus price target as assigned by Wall Street analysts is $93.5, which translates to bulls needing to increase their stock price by 57.42% from its current value. Analyst projections state that CYTK is forecast to be at a low of $67 and a high of $120.
Cytokinetics Inc (CYTK) estimates and forecasts
The year-over-year growth rate is expected to be 93.30%, up from the previous year.
Consensus estimates provided by 16 financial analysts predict the company will bring in an average of 2.77M in revenue for the current quarter. 16 analysts expect Cytokinetics Inc to make 2.96M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 835k and 249k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 232.15%. Forecasts for the next quarter put sales growth at 1,089.48%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -20.02%. Cytokinetics Inc earnings are expected to increase by -8.38% in 2025, but the outlook is positive 19.31% per year for the next five years.
CYTK Dividends
Cytokinetics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-26.
Cytokinetics Inc (NASDAQ:CYTK)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.72% of Cytokinetics Inc shares, and 114.19% of them are in the hands of institutional investors. The stock currently has a share float of 115.02%. Cytokinetics Inc stock is held by 479.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 13.4317% of the shares, which is about 14.67 million shares worth $794.97 million.
VANGUARD GROUP INC, with 11.2218% or 11.44 million shares worth $619.69 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
